Skip to main content

Table 4 Incidence rates of HZ complications (per 100,000 persons - year), overall and by age groups and IC condition

From: Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009–2014

IC condition

Incidence rate of HZ complications per 100,000 PY (95% CI)

18–29

30–39

40–49

50–59

60–69

70–79

≥ 80

Overall

Population

0.35 (0.18–0.59)

0.75 (0.53–1.04)

1.09 (0.81–1.44)

1.34 (0.99–1.77)

4.34 (3.63–5.15)

10.89 (9.6–12.31)

21.35 (19.08–23.81)

3.63 (3.39–3.88)

IC-free cohort

0.33 (0.17–0.58)

0.49 (0.3–0.73)

0.47 (0.29–0.73)

0.78 (0.51–1.15)

2.95 (2.33–3.68)

8.48 (7.25–9.85)

18.78 (16.49–21.3)

2.64 (2.42–2.86)

IC cohort

0.58 (0.01–3.21)

5.55 (3.04–9.32)

9.74 (6.57–13.9)

6.91 (4.38–10.37)

14.3 (10.71–18.7)

24.76 (19.83–30.54)

36.12 (28.68–44.89)

14.36 (12.75–16.11)

HSCT

310.46 (7.86–1729.79)

161.25 (4.08–898.45)

759.63 (305.41–1565.13)

161.39 (19.55–583)

232.54 (47.95–679.57)

0 (0–1492.1)

0 (0–25,474.82)

300.77 (164.43–504.63)

SOT

0 (0–112.66)

38.5 (7.94–112.52)

41.92 (13.61–97.83)

35.98 (11.68–83.97)

90.74 (49.61–152.25)

50.33 (18.47–109.55)

36.08 (4.37–130.34)

50.16 (34.94–69.76)

HN

4.13 (0.1–23)

10.68 (2.2–31.22)

40.77 (20.35–72.95)

15.49 (4.22–39.65)

47.43 (25.93–79.58)

51.98 (29.09–85.73)

52.86 (25.35–97.22)

31.8 (24.15–41.11)

SON

13.14 (0.33–73.22)

8 (0.97–28.91)

9.69 (3.56–21.1)

6.69 (2.89–13.19)

11.9 (7.46–18.01)

22.86 (16.86–30.31)

36.96 (27.84–48.1)

18.74 (15.79–22.09)

NEOPLASIAS

3.1 (0.08–17.3)

7.39 (2.01–18.91)

16.95 (9.49–27.96)

7.66 (3.82–13.71)

14.68 (9.97–20.83)

25.14 (19.14–32.43)

38.84 (29.91–49.6)

19.91 (17.15–23)

HIV

0 (0–131.63)

54.1 (19.85–117.76)

37.1 (16.96–70.43)

37.36 (10.18–95.65)

98.64 (20.34–288.25)

95.01 (2.41–529.36)

0 (0–1269.77)

43.2 (27.38–64.82)

AUTOIMMUNE

0.71 (0.02–3.96)

3.15 (1.16–6.86)

7.91 (4.52–12.84)

4.25 (1.83–8.37)

15.32 (10.01–22.45)

25.27 (17.39–35.48)

30.81 (19.07–47.09)

10.18 (8.37–12.26)

RA

0 (0–58.05)

8.28 (0.21–46.11)

4.5 (0.11–25.08)

3.15 (0.08–17.56)

11.08 (3.02–28.37)

27.05 (12.37–51.36)

40.7 (17.57–80.2)

14.87 (9.53–22.12)

SLE

0 (0–244.45)

25.12 (0.64–139.94)

38.74 (4.69–139.92)

24.55 (0.62–136.78)

0 (0–136.77)

61.59 (1.56–343.18)

0 (0–461.25)

25.19 (8.18–58.79)

IBD

0 (0–30.57)

4.17 (0.11–23.23)

3.84 (0.1–21.39)

0 (0–18.68)

18.94 (3.91–55.34)

15.59 (1.89–56.3)

29.53 (3.58–106.69)

7.67 (3.51–14.57)

PSORIASIS

0 (0–3.86)

0 (0–3.42)

0.99 (0.03–5.52)

2.27 (0.27–8.19)

6.63 (2.15–15.48)

7.88 (2.15–20.17)

35.83 (15.47–70.6)

3.7 (2.26–5.71)

MS

0 (0–220.87)

0 (0–71.54)

0 (0–59.58)

0 (0–85.36)

38.62 (0.98–215.15)

0 (0–344.05)

0 (0–1436.88)

4.7 (0.12–26.21)

AT

0 (0–123.35)

15.73 (0.4–87.64)

0 (0–47.47)

0 (0–46.07)

0 (0–64.98)

0 (0–117.91)

0 (0–322.51)

2.85 (0.07–15.89)

  1. CI Confidence interval, IC immunocompromised, HSCT haematopoietic stem cell transplant, SOT solid organ transplantation, HN haematological neoplasia, SON solid organ neoplasia, NEOPLASIAS neoplasias overall, HIV human immunodeficiency virus, AUTOIMMUNE RA rheumatoid arthritis, SLE systemic lupus erythematosus, IBD Inflammatory bowel disease, MS multiple sclerosis, AT autoimmune thyroiditis, AUTOIMMUNE immunodeficiency disorders and autoimmune diseases overall (See supplementary Table 1)